Increlex: Research, Dosing, and Where to Buy in 2026
A research-first profile for Increlex (inklex, increx, ink), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Increlex is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 5 PubMed-cited papers, and 1 transcript dosing protocol for Increlex, each linked to its source.
- Also indexed as inklex, increx, ink.
- 1 aggregated dosing-protocol mention from source transcripts.
- 5 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Increlex?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Increlex Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve | Injectable SLU, AI Dosing Protocol, Glutathione & NAD+, GH & Insulin... | 00:26:37 | Steve reported using 40-120 mcg/kg body weight with the goal of reaching the top of the reference IGF-1 range (e.g., 4-12 mg/day for a 100 kg user). | anecdotal |
Where to Buy Increlex in 2026
No tracked vendor recommendations for Increlex yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Increlex. Each line links to the original source.
- "Despite improved height in patients with Laron syndrome, only 10.5% reached NAH within the normal range; 3 patients with Laron syndrome were NPP." · Ramon-Krauel M et al, 2026 PubMed
- "Noteworthy, rhIGF-1 was shown to efficiently induce development of Laron patients achieving at least proper rate of growth (compared to healthy group) in 80% of subjects." · Kamil G et al, 2023 PubMed
- "Mean ± SD (95% CI) height velocity during first year of rhIGF-1 treatment was 6.9 ± 2.2 cm/year (6.5; 7.2) (n = 144); in prepubertal patients naïve to treatment, this was 7.3 ± 2.0 cm/year (6.8; 7.7) (n = 81)." · Bang P et al, 2015 PubMed
- "The most frequent targeted treatment-emergent adverse events (% patients) were hypoglycemia (17.6%, predictors: young age, diagnosis of Laron syndrome, but not rhIGF-1 dose), lipohypertrophy (10.6%), tonsillar hypertrophy (7.4%), injection site reactions (6.4%), and headache (5.9%)." · Bang P et al, 2015 PubMed
- "Sixty-one serious adverse events (37 related to rhIGF-1 therapy) were reported in 31 patients (16.5%)." · Bang P et al, 2015 PubMed
Increlex Research Findings in Numbers
Quantitative results quoted verbatim from the indexed peer-reviewed studies and attributed clinical protocols below.
- Steve reported using 40-120 mcg/kg body weight with the goal of reaching the top of the reference IGF-1 range (e.g., 4-12 mg/day for a 100 kg user). Steve
- Mean age at rhIGF-1 treatment initiation was 11.8 years PMID 40626687
- median treatment duration was 3.9 years. PMID 40626687
- A Moroccan girl referred for short stature at 7 years and 8 months of age had dwarfism [height, 78 cm (-9 SDs) PMID 22986916
- weight, 10 kg (-4 SDs)], hypoglycemia, and truncal obesity. PMID 22986916
- Continuous glucose monitoring before treatment showed asymptomatic hypoglycemia with postprandial hyperglycemia (2.5 g/l, 13.75 mmol/l). PMID 22986916
Research and Studies
5 PubMed-indexed papers reference Increlex. Top 5 shown.
Legal Status
Increlex is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-16.
Frequently Asked Questions
Is Increlex FDA-approved?
Increlex is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Increlex?
This page aggregates 1 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Increlex?
5 PubMed-indexed paper(s) reference Increlex in our current research feed. See the Research and Studies section above for citations.